BiotechTube

NYESO-1c259 T cells

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ovarian Cancer

Conditions

Ovarian Cancer

Trial Timeline

Jul 9, 2013 → Jun 6, 2017

NCT ID
NCT01567891

About NYESO-1c259 T cells

NYESO-1c259 T cells is a phase 1/2 stage product being developed by Adaptimmune Therapeutics for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01567891. Target conditions include Ovarian Cancer.

What happened to similar drugs?

11 of 20 similar drugs in Ovarian Cancer were approved

Approved (11) Terminated (4) Active (7)
✅OlaparibAstraZenecaApproved
✅OlaparibAstraZenecaApproved
✅Olaparib + BevacizumabAstraZenecaApproved
✅Ganirelix acetateMerckApproved
✅Triptorelin 0.2 mgMerckApproved
✅Pegylated Liposomal Doxorubicin hydrochlorideMerckApproved
✅fosaprepitant + aprepitantMerckApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01567891Phase 1/2Completed

Competing Products

20 competing products in Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
mRNA-2416ModernaPhase 2
0
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
azenosertibZentalis PharmaceuticalsPhase 2
32
Azenosertib + NiraparibZentalis PharmaceuticalsPhase 1/2
22
pemetrexed + topotecanEli LillyPhase 1
29
arzoxifene hydrochlorideEli LillyPhase 2
35
LY4337713Eli LillyPhase 1
36
PrexasertibEli LillyPhase 2
35
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabBioAtlaPhase 2
32
Gemcitabine + Oxaliplatin + BevacizumabEli LillyPhase 2
27
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
39
Trastzumab Deruxtecan + Bevacizumab + Platinum Based ChemotherapyDaiichi SankyoPhase 2
42
Trastuzumab Deruxtecan + BevacizumabDaiichi SankyoPhase 3
47
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
CS-1008 + Paclitaxel + CarboplatinDaiichi SankyoPhase 2
35
OSI-906 + PaclitaxelAstellas PharmaPhase 1/2
32
Enzalutamide 40 MGAstellas PharmaPhase 2
35
ASP0739Astellas PharmaPhase 1/2
24
IMAB027Astellas PharmaPhase 1
29